The goal of Dozee’s partnership with BII is to improve access to healthcare across India and alleviate the workload of healthcare workers, reduce nurse burnout and fatigue in hospital wards
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
The company is one of the most profitable companies manufacturing speciality chemicals in India
Krishna Institute of Medical Sciences to consider raising Rs. 300 crores
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
The scheme is subject to statutory and regulatory approvals as may be necessary.
Subscribe To Our Newsletter & Stay Updated
